Brief: Verrica Pharmaceuticals Reports Fourth Quarter And Full-Year 2022 Financial Results

Verrica Pharmaceuticals

06/03/2023 12:36

March 6 (Reuters) - Verrica Pharmaceuticals Inc
 VRCA.O :
    * VERRICA PHARMACEUTICALS REPORTS FOURTH QUARTER AND
FULL-YEAR
2022 FINANCIAL RESULTS
    * NEW DRUG APPLICATION FOR VP-102 ASSIGNED PDUFA GOAL DATE
OF JULY
23, 2023
    * DOSING OF FIRST PATIENT IN PART 2 OF PHASE 2 STUDY OF
VP-315 FOR
TREATMENT OF BASAL CELL CARCINOMA EXPECTED IN 2Q 2023
    * PRO FORMA CASH AND CASH EQUIVALENTS TO FUND PLANNED
OPERATIONS
INTO 1Q 2024
    * AS OF DECEMBER 31, 2022, VERRICA HAD AGGREGATE CASH AND
CASH
EQUIVALENTS OF $34.3 MILLION
    * BELIEVES IT HAS SUFFICIENT CASH AND CASH EQUIVALENTS TO
SUPPORT
PLANNED OPERATIONS INTO Q1 OF 2024
    * QTRLY LOSS PER SHARE $0.14
    * Q4 EARNINGS PER SHARE VIEW $-0.19 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX3f9SRy 
Further company coverage:  VRCA.O 

 ((Reuters.Briefs@thomsonreuters.com;))